** Shares of medical technology co Artrya AYA.AX rise 9.4% to A$0.875
** Stock hits its highest level since January 20
** Co secures U.S. Food and Drug Administration (FDA) clearance for commercial sale of Salix Coronary Anatomy in the United States
** Salix is the first point of care approach for assessing coronary artery disease, says co
** About 1.9 million shares change hands, 9.7 times the 30-day average volume of shares
** Stock up 50.9% this year, as of last close
(Reporting by Sherin Sunny in Bengaluru)
((Sherin.Sunny@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.